Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Crispr Therapeutics AG (CRSP) vs VNET Group Inc (VNET) Price & Performance

Crispr Therapeutics AGTrade
VNET Group IncTrade

Price performance (Past 24H)

Key statistics

Crispr Therapeutics AG vs VNET Group Inc — how do they compare? Crispr Therapeutics AG trades at $53.93 (market cap $5.23B), while VNET Group Inc trades at $7.38 (market cap $2.14B). The key difference: Crispr Therapeutics AG is far larger — about 2.4× VNET Group Inc's market cap, and Crispr Therapeutics AG is trading nearer its 52-week high, VNET Group Inc nearer its low. Which is the better fit depends on your goals.

CRSPVNET
Market Cap
$5.23B$2.14B
Sector
HealthTechnology
52-Week High
$76.78$14.03
52-Week Low
$44.34$6.29
Enterprise Value
$3.65B$5.29B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Crispr Therapeutics AG

CRISPR Therapeutics (CRSP) trades at $53.83, up 0.6% on the day, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a Q2 2026 EPS beat with a loss of $0.94 versus an expected $1.19 loss, driven by surging CASGEVY sales. However, financials show deep losses, with a net income margin of -4,101.26% in 2025 and negative operating cash flow, though financing activities provided liquidity.

The outlook is mixed: strong analyst consensus (57.9% buy ratings) and a $82.67 price target reflect optimism around CASGEVY growth and pipeline catalysts, but high valuation (P/S of 466.05) and persistent cash burn pose significant risks. Investment appeal hinges on successful clinical advancements and path to profitability.

VNET Group Inc

VNET trades at $7.40, down 1.07% today, with a neutral technical signal and bearish moving averages. The company reported a net loss of $256.77 million in 2025, with negative profit margins and ROE, though revenue grew to $9.95 billion. Recent news highlights strategic investor entry and AI-driven demand boosting wholesale data center growth.

The outlook is mixed: analyst consensus is 62.5% buy with a 54% upside target, but persistent losses and high debt pose risks. Investment opportunity hinges on execution of capacity expansion and AI demand, while investors face volatility from earnings misses and competitive pressures in China's data center market.

Returns comparison

Trailing returns across standard periods

About Crispr Therapeutics AG

CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.

Read more on CRSP

About VNET Group Inc

VNET Group, formerly 21Vianet, is a leading carrier-neutral data center services provider in China. It operates a dual-core strategy: a large-scale retail business serving over 7,000 enterprise customers and an aggressive wholesale segment (Hyperscale 2.0) designed to meet the high-density power and cooling demands of large-scale AI and cloud platforms.

Read more on VNET